Quick Facts: Spazgan Therapeutic Domains

• May be considered for the management of symptoms associated with intestinal colic.
• Used in therapeutic protocols addressing pain and spasms of the genitourinary system, such as renal colic.
• An option for the symptomatic relief of pain linked to biliary tract disorders, including biliary colic.
• Supports the alleviation of discomfort that may occur with certain smooth muscle contractions.

What Спазган Treats: Main Uses and Benefits

Спазган (Spazgan) is a prescription medication primarily intended for the symptomatic management of pain associated with smooth muscle spasms. It is intended for short-term use in adults and acts as an agent to help relieve acute instances of discomfort.

The medication is utilized in the therapeutic domain of the gastrointestinal tract, where it may be considered for the alleviation of symptoms related to intestinal colic and certain manifestations of irritable bowel syndrome. Additionally, this compound is employed to address pain and spasms originating in the genitourinary system, such as in cases of renal colic or painful menstrual cramping (dysmenorrhea). Its applications also extend to providing relief for discomfort associated with the biliary tract, including episodes of biliary colic and cholecystitis.

Clinical guidelines indicate the compound is part of the established therapeutic options for severe, acute smooth muscle pain. As a prescription agent, it is integrated into comprehensive pain management plans to support relief from various types of colic and spasms.

Regulatory References

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306558/

Eligibility Map: Who Can and Cannot Use Спазган — Official Regulatory Information

This section outlines the official population eligibility and non-eligibility status for Спазган, based strictly on government regulatory documents.

Resulting Eligibility Structure

Official regulatory documents establish three tiers of use: absolute prohibition, conditional restriction, and eligible use. Absolute prohibition applies to patients with a history of severe blood disorders or those in late-stage pregnancy. Conditional use, often requiring caution, applies to populations with organ impairment (e.g., renal/hepatic function) or those in early pregnancy. Eligible use is generally defined for adults and adolescents from 15 years of age.

Interactions with other medicines and products

Спазган is a combination product containing metamizole, pitofenone, and fenpiverinium, and its interaction profile is primarily driven by metamizole (a pyrazolone derivative).

Contraindicated Combinations

• Concomitant use with other pyrazolone derivatives or Non-Steroidal Anti-inflammatory Drugs (NSAIDs) should be avoided due to an increased risk of severe adverse reactions.

Clinically Significant Interactions

• Metamizole can reduce the plasma concentration of Ciclosporin (Cyclosporine), potentially requiring therapeutic drug monitoring and dose adjustment of the immunosuppressant. This is thought to be due to induction of hepatic enzymes.
• The drug may enhance the effect of oral anticoagulants (e.g., Warfarin) and oral antidiabetic agents by displacing them from plasma protein binding sites.
• Co-administration with Methotrexate may increase the risk of toxicity, especially hematological side effects, necessitating close monitoring.
• Enzyme inducers (e.g., Barbiturates, Phenylbutazone) may diminish the therapeutic effect of metamizole by accelerating its metabolism.
• The combination with Chlorpromazine or other phenothiazine derivatives may lead to severe hypothermia.
• The effects of tricyclic antidepressants and combined oral contraceptives may be potentiated.
• Alcohol (Ethanol) consumption must be avoided, as the components of Спазган may mutually potentiate its effects.

Spazgan exerts its effects through the combined action of its components, primarily targeting two distinct physiological domains: prostanoid synthesis and smooth muscle contractility.### Targeting Prostanoid Synthesis for Systemic EffectsThe component Metamizole modulates specific signaling responses by inhibiting select enzyme isoforms, particularly cyclooxygenase, involved in the biosynthesis of prostanoids within the central nervous system. Prostanoids are lipid mediators that influence subsequent physiological responses. This mechanistic cascade results in an altered local concentration of these mediators, which influences subsequent systemic effects. ### Modulating Smooth Muscle Activity via Muscarinic ReceptorsThe combination of Pitofenone and Fenpiverinium bromide directly affects smooth muscle contraction. Pitofenone acts as a spasmolytic by engaging mechanisms that inhibit muscular contraction, primarily through competitive binding to muscarinic acetylcholine receptors on smooth muscle cells. Fenpiverinium enhances this action via its quaternary ammonium structure, which further modulates cholinergic signaling input to the smooth muscle, affecting contractile force. The overall consequence is a decrease in smooth muscle tonicity.

How to Use Спазган: Official Administration Guidelines

This section outlines the protocols for the use of this combined analgesic-antispasmodic. The medication is available for administration via two primary pathways: the oral route (tablet) and the parenteral route, which includes both intramuscular (IM) and intravenous (IV) injection.

The usage protocol is defined by two distinct administration pathways—oral and parenteral—each with defined single and maximum daily limits. This framework dictates that the medicine is reserved for acute, short-term application. Adherence to procedural details, such as the required slow infusion rate for intravenous administration and mandated dose reductions for organ impairment, supports the standardized application of the treatment.

Research evidence / Overview of studies for Спазган (Spazgan)

Evidence for use in Acute Renal Colic Pain

The research conducted for the primary analgesic component in Спазган, Metamizole, often involves studies on acute, severe pain. This type of research is relevant in trials assessing short-term or episodic symptom patterns in conditions associated with acute or disruptive episodes, such as renal colic.

Studies conducted during periods of increased symptom activity in adult patients often take the form of single-dose, short-term Randomized Controlled Trials (RCTs). These research examined outcomes related to physical discomfort by monitoring changes in patient-reported pain intensity scores. The primary outcome examined in these trials is the change in pain intensity. Data from some studies reported measured pain changes when contrasted with other analgesics used for acute renal colic pain in the study settings.

Evidence for use in Other Spasm-Related Conditions

For other conditions characterized by fluctuating or episodic manifestations involving smooth muscle spasm—such as biliary colic, intestinal colic, and painful menstrual cramping (dysmenorrhea)—the research base is generally less direct for the specific triple combination drug.

Studies have explored the effects of Metamizole monotherapy in these contexts. Clinical support for these indications often relies on the documented actions of the individual components (analgesic and spasmolytic). Dedicated comparative randomized controlled trials for the specific triple combination in indications such as biliary colic or severe dysmenorrhea are not frequently found in major systematic reviews.

What is Still Uncertain About the Research Base

While research describes patterns related to short-term pain relief, several limitations and uncertainties exist in the evidence base. Comparative evidence is lacking for the specific triple-component formulation (Metamizole/Pitofenone/Fenpiverinium) when weighed against Metamizole used alone. Available data reported mixed findings on whether the addition of spasmolytics provides a consistent, measurable difference in acute pain relief over the analgesic component alone. Furthermore, the overall evidence base is often limited by factors such as design constraints and modest sample sizes.

Key Studies & References The Antispasmodic/Analgesic Combination Fenpiverinium Bromide-Pitofenone-Metamizole Sodium in the Treatment of Acute Spasmodic Pain: A Review of the Evidence

Common questions about Спазган (FAQ)

Q: What is the onset of action and how long do the effects of a single dose of Спазган last?

Official information regarding the main analgesic component, Metamizole, indicates rapid absorption. It typically reaches its maximum concentration in the blood within approximately 1.4 to 2.0 hours after an oral dose.

Pharmacokinetic studies indicate that the half-life of the active metabolite, which describes the duration it remains in the system, is reported to be in the range of 2.6 to 3.5 hours.

Q: Why is it recommended to take the oral tablets after eating?

The official administration guidelines state that oral tablets are to be taken with water after eating.

While the instructions are specific, this practice is commonly recommended for certain types of medication to help minimize the potential for general gastrointestinal discomfort or irritation.

Q: How quickly do I need to stop taking the drug if I develop a fever or a rash?

The official safety information requires that treatment be discontinued immediately and permanently upon the first sign of a severe adverse reaction.

This includes the sudden onset of an unexplained fever, chills, sore throat, or the development of a severe skin rash or lesions. Seeking urgent medical assistance is mandated in these situations.

Q: If I miss a dose of Спазган, what should I do?

General regulatory guidance for scheduled medications often suggests that if a dose is missed, the medication should be taken as soon as it is remembered.

However, if the time is almost right for the next scheduled dose, the missed dose should be skipped entirely. It is officially advised not to take a double dose to compensate for a missed dose.

Q: What should I do if I suspect a drug overdose?

In the event a drug overdose is suspected, official regulatory protocol requires that emergency medical attention be sought immediately.

This involves contacting a local poison control center or seeking urgent help at a healthcare facility.

Q: Are there any known long-term side effects if I use Спазган for an extended period?

This medicine is officially reserved for acute, short-term application.

Because of its intended use, there is limited data on the safety profile for prolonged treatment. If use extends beyond short-term application, close medical supervision and monitoring are required, according to regulatory documents.

Q: What are the signs or symptoms of agranulocytosis that should prompt me to stop taking Спазган?

Official warnings state that the medicine should be immediately discontinued if signs of a serious blood disorder, like agranulocytosis, appear.

Symptoms listed in regulatory guidance include an unexplained fever, chills, sore throat, or the presence of painful sores on the moist inner linings of the body, such as in the mouth or throat.

How to Store and Dispose of Спазган?

This information is based on official regulatory requirements for the combination product containing Metamizole sodium, Pitofenone hydrochloride, and Fenpiverinium bromide.

Official Storage Conditions

The medicine must be stored at a temperature below 25°C. To ensure product integrity, it is mandatory to keep the tablets in the original container and protect from light and moisture.

Child Safety and Stability

It is required to keep the medicine out of reach of children. The product must not be used after the expiry date printed on the carton and blister.

Disposal Requirements

Do not dispose of unused or expired medicine in wastewater or with household waste. Consult a pharmacist for instructions on how to properly discard the medication, as these specialized measures are required to help protect the environment.